Biofrontera (BFRI) Competitors $0.83 -0.02 (-2.09%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRI vs. SNYR, ELEV, PULM, TNXP, MRNS, VRCA, UBX, IRD, AKTX, and GDTCShould you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include Synergy CHC Corp. (Uplisting) (SNYR), Elevation Oncology (ELEV), Pulmatrix (PULM), Tonix Pharmaceuticals (TNXP), Marinus Pharmaceuticals (MRNS), Verrica Pharmaceuticals (VRCA), Unity Biotechnology (UBX), Opus Genetics (IRD), Akari Therapeutics (AKTX), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Biofrontera vs. Synergy CHC Corp. (Uplisting) Elevation Oncology Pulmatrix Tonix Pharmaceuticals Marinus Pharmaceuticals Verrica Pharmaceuticals Unity Biotechnology Opus Genetics Akari Therapeutics CytoMed Therapeutics Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) and Biofrontera (NASDAQ:BFRI) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Is SNYR or BFRI more profitable? Synergy CHC Corp. (Uplisting) has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC Corp. (Uplisting)N/A N/A N/A Biofrontera -36.31%-565.73%-96.64% Does the media favor SNYR or BFRI? In the previous week, Biofrontera had 7 more articles in the media than Synergy CHC Corp. (Uplisting). MarketBeat recorded 8 mentions for Biofrontera and 1 mentions for Synergy CHC Corp. (Uplisting). Synergy CHC Corp. (Uplisting)'s average media sentiment score of 0.94 beat Biofrontera's score of 0.58 indicating that Synergy CHC Corp. (Uplisting) is being referred to more favorably in the media. Company Overall Sentiment Synergy CHC Corp. (Uplisting) Positive Biofrontera Positive Which has preferable earnings & valuation, SNYR or BFRI? Synergy CHC Corp. (Uplisting) has higher earnings, but lower revenue than Biofrontera. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC Corp. (Uplisting)$26.01M0.97N/AN/AN/ABiofrontera$37.32M0.19-$20.13M-$2.26-0.36 Do institutionals and insiders believe in SNYR or BFRI? 10.1% of Biofrontera shares are owned by institutional investors. 0.2% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate SNYR or BFRI? Synergy CHC Corp. (Uplisting) currently has a consensus target price of $10.00, indicating a potential upside of 244.83%. Biofrontera has a consensus target price of $7.00, indicating a potential upside of 761.01%. Given Biofrontera's higher probable upside, analysts clearly believe Biofrontera is more favorable than Synergy CHC Corp. (Uplisting).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor SNYR or BFRI? Biofrontera received 6 more outperform votes than Synergy CHC Corp. (Uplisting) when rated by MarketBeat users. CompanyUnderperformOutperformSynergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% BiofronteraOutperform Votes866.67% Underperform Votes433.33% SummarySynergy CHC Corp. (Uplisting) beats Biofrontera on 7 of the 13 factors compared between the two stocks. Remove Ads Get Biofrontera News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRI vs. The Competition Export to ExcelMetricBiofronteraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.22M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-0.367.1723.3318.67Price / Sales0.19220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.266.396.894.23Net Income-$20.13M$142.12M$3.20B$247.15M7 Day Performance-5.47%-5.18%-3.02%-2.17%1 Month Performance-16.64%-7.49%1.63%-5.68%1 Year Performance-47.21%-8.78%9.74%-0.67% Biofrontera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRIBiofrontera2.3148 of 5 stars$0.81-4.1%$7.00+761.0%-26.3%$7.22M$37.32M-0.3670Short Interest ↑SNYRSynergy CHC Corp. (Uplisting)3.5867 of 5 stars$3.58+0.8%$10.00+179.3%N/A$31.16M$26.01M0.0040ELEVElevation Oncology2.4238 of 5 stars$0.53-1.3%$6.83+1,199.4%-94.8%$31.14MN/A-0.6440PULMPulmatrix0.2115 of 5 stars$8.39-0.8%N/A+341.8%$30.62M$10.01M-3.1820Earnings ReportPositive NewsTNXPTonix Pharmaceuticals2.4508 of 5 stars$16.28+8.5%$1,100.00+6,656.8%-97.5%$30.43M$11.29M0.0050Short Interest ↑Gap DownMRNSMarinus Pharmaceuticals2.3345 of 5 stars$0.55-0.2%$4.79+771.6%-93.8%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageVRCAVerrica Pharmaceuticals4.2442 of 5 stars$0.65+21.1%$9.50+1,360.4%-92.3%$29.66M$7.57M-0.3640UBXUnity Biotechnology4.1241 of 5 stars$1.75-1.1%$7.33+319.0%-27.6%$29.52M$240,000.00-1.3460Analyst ForecastAnalyst RevisionIRDOpus Genetics2.3129 of 5 stars$0.94+0.7%$8.00+749.6%N/A$29.51M$8.38M-0.8614AKTXAkari TherapeuticsN/A$1.10+1.9%N/A-27.8%$29.25MN/A0.009Upcoming EarningsAnalyst ForecastGDTCCytoMed Therapeutics2.4754 of 5 stars$2.65+6.9%$5.00+88.7%+0.7%$28.99MN/A0.00N/AShort Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies SNYR Competitors ELEV Competitors PULM Competitors TNXP Competitors MRNS Competitors VRCA Competitors UBX Competitors IRD Competitors AKTX Competitors GDTC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech fir...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
